Next Article in Journal
Computed Tomography-Guided Cryoablation of Local Recurrence after Primary Resection of Pancreatic Adenocarcinoma
Previous Article in Journal
Rare Presentation of Gall Bladder Tuberculosis in a Non Immuno-Compromised Patient
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Clinics and Practice
Volume 5
Issue 2
10.4081/cp.2015.756
clinpract-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Clinics and Practice is published by MDPI from Volume 11 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Use of Recombinant Factor VIIa in Symptomatic Intracerebral Hemorrhage Following Intravenous Thrombolysis

by
Shadi Yaghi
*,
Aya Haggiagi
,
Ayesha Sherzai
,
Randolph S. Marshall
and
Sachin Agarwal
Department of Neurology, Columbia University Medical Center, New York, NY, USA
*
Author to whom correspondence should be addressed.
Clin. Pract. 2015, 5(2), 756; https://doi.org/10.4081/cp.2015.756
Submission received: 1 February 2015 / Revised: 12 March 2015 / Accepted: 16 April 2015 / Published: 18 June 2015

Abstract

Symptomatic intracerebral hemorrhage (sICH) occurs in up to 7% of stroke patients treated with thrombolytic therapy. There are limited data on the effectiveness of the reversal agents used for intravenous tissue plasminogen activator related intracranial bleeds. We report a patient with sICH following intravenous thrombolysis whose intracerebral hemorrhage continued to expand despite treatment with platelets and cryoprecipitate, needing recombinant factor VIIa use for stabilization before surgical evacuation. Factor VIIa along with routine reversal agents following intravenous thrombolysis related sICH may further enhance clot stability and reduce the risk of hematoma expansion. It could be a bridge to definitive surgical management in those patients.
Keywords: intracerebral hemorrhage; ischemic stroke; thrombolysis; factor VIIa; outcome; expansion intracerebral hemorrhage; ischemic stroke; thrombolysis; factor VIIa; outcome; expansion

Share and Cite

MDPI and ACS Style

Yaghi, S.; Haggiagi, A.; Sherzai, A.; Marshall, R.S.; Agarwal, S. Use of Recombinant Factor VIIa in Symptomatic Intracerebral Hemorrhage Following Intravenous Thrombolysis. Clin. Pract. 2015, 5, 756. https://doi.org/10.4081/cp.2015.756

AMA Style

Yaghi S, Haggiagi A, Sherzai A, Marshall RS, Agarwal S. Use of Recombinant Factor VIIa in Symptomatic Intracerebral Hemorrhage Following Intravenous Thrombolysis. Clinics and Practice. 2015; 5(2):756. https://doi.org/10.4081/cp.2015.756

Chicago/Turabian Style

Yaghi, Shadi, Aya Haggiagi, Ayesha Sherzai, Randolph S. Marshall, and Sachin Agarwal. 2015. "Use of Recombinant Factor VIIa in Symptomatic Intracerebral Hemorrhage Following Intravenous Thrombolysis" Clinics and Practice 5, no. 2: 756. https://doi.org/10.4081/cp.2015.756

APA Style

Yaghi, S., Haggiagi, A., Sherzai, A., Marshall, R. S., & Agarwal, S. (2015). Use of Recombinant Factor VIIa in Symptomatic Intracerebral Hemorrhage Following Intravenous Thrombolysis. Clinics and Practice, 5(2), 756. https://doi.org/10.4081/cp.2015.756

Article Metrics

Back to TopTop